Drug firm Jubilant Life Sciences today said US health regulator has issued a warning letter for violation of manufacturing norms at its facility in Canada.
"Jubilant HollisterStier General Partnership (JHS) located at Kirkland, Quebec, Canada has been issued a warning letter (WL) by US Food and Drug Administration (FDA) identifying significant violations of current good
As required by FDA, JHS will respond to this letter by March 15, 2013, it added.
"The response will provide details as to what corrective action has already been completed, as well as, additional detail as to how the facility will prevent the re occurrence of the items found to be objectionable to the FDA," Jubilant Life Sciences said.
USFDA had specified in its letter that until all corrections have been completed, it may withhold approval of new applications or supplements listing JHS as the drug product manufacturer.
"We expect that the on-going manufacturing, distribution and sale of products will not be affected by this warning letter. JHS is committed to implementing the necessary corrective actions required to address the FDA concerns, and
Shares of Jubilant Life Sciences today closed at Rs 176.45 per scrip on BSE, down sharp 4.90 percent from its previous close.
Jubilant Life stock price
On November 30, 2015, at 15:43 hrs Jubilant Life Sciences was quoting at Rs 412.20, up Rs 4.35, or 1.07 percent. The 52-week high of the share was Rs 435.50 and the 52-week low was Rs 126.25.
The latest book value of the company is Rs 122.11 per share. At current value, the price-to-book value of the company was 3.38.
Set email alert for
ADS BY GOOGLE
video of the day
Mkt resilient at current level; bullish auto: ICICI Pru AMC